duchenn
becker
muscular
dystrophi
dmd
bmd
xlink
recess
musclewast
diseas
aris
mutat
massiv
dystrophin
gene
dmd
lead
degener
muscl
dmd
preval
sever
form
childhood
muscl
wast
cite
incid
livemal
birth
wherea
bmd
clinic
milder
form
diseas
slower
diseas
progress
bmd
mutat
may
present
spectrum
phenotyp
depend
upon
natur
locat
dmd
lesion
bmd
mutat
usual
disrupt
read
frame
therebi
allow
product
intern
shorten
function
dystrophin
bmd
patient
remain
ambul
least
year
age
mild
asymptomat
case
may
diagnos
accid
late
life
convers
intermedi
muscular
dystrophi
use
describ
mildli
affect
dmd
patient
whose
genet
structur
would
predict
prematur
truncat
dystrophin
loss
ambul
year
age
sever
affect
bmd
case
would
expect
produc
function
dystrophin
therefor
remain
ambul
year
age
dubowitz
state
intermedi
dmd
patient
defin
patient
dystrophinopathi
onset
symptom
motor
difficulti
year
age
similar
classic
dmd
patient
slower
rate
diseas
progress
loss
ambul
year
age
children
age
vari
wide
clinic
present
patient
appear
milder
dystrophinopathi
also
term
outlier
dmd
case
correl
diseas
phenotyp
genotyp
obviou
howev
except
read
frame
rule
infram
delet
may
result
sever
phenotyp
convers
outoffram
gene
rearrang
nonsens
mutat
present
rel
mild
symptom
consist
diagnosi
bmd
pathogen
basi
particular
infram
dystrophin
delet
reflect
number
exon
lost
delet
exon
usual
associ
sever
patholog
secondari
effect
premrna
process
infram
delet
may
sever
consequ
due
loss
crucial
function
domain
within
dystrophin
eg
actin
betadystroglycan
bind
region
mutat
region
dmd
gene
frequent
manifest
except
read
frame
rule
variou
mechan
propos
impact
consequ
mutat
includ
reiniti
translat
splice
perturb
gualandi
colleagu
report
loss
dmd
exon
compromis
premrna
process
select
exon
consist
sever
dystroph
phenotyp
describ
anoth
patient
carri
genom
delet
dmd
exon
manifest
moderatesever
phenotyp
despit
detect
dystrophin
demonstr
immunofluoresc
show
dmd
transcript
patient
miss
exon
genom
loss
exon
obvious
alter
recognit
splice
exon
small
number
patient
miss
dmd
exon
describ
therefor
opportun
explor
phenotyp
variat
perhap
understand
basi
sever
expect
diseas
limit
order
evalu
dystrophin
isoform
lack
actin
bind
domain
encod
exon
induc
transient
dystrophinopathi
model
skip
dmd
exon
wildtyp
mice
analysi
dystrophin
compon
dystrophinassoci
glycoprotein
complex
muscl
architectur
isol
muscl
function
reveal
moder
dystroph
chang
diaphragm
intermedi
mdx
wildtyp
phenotyp
excis
dmd
exon
greatli
reduc
dystrophin
express
mous
diaphragm
compromis
muscl
function
target
exon
skip
emerg
promis
therapi
treat
dmd
time
focu
exclus
exon
flank
frame
shiftingdelet
order
refram
transcript
similarli
remov
infram
exon
carri
intraexon
protein
truncat
mutat
duplic
infram
exon
would
allow
synthesi
function
dystrophin
isoform
rational
refram
dmd
transcript
produc
bmdlike
isoform
reduc
diseas
sever
examin
bmd
phenotyp
genotyp
correl
indic
dmd
transcript
structur
like
gener
function
dystrophin
isoform
therefor
inform
exon
skip
strategi
propos
remov
dmd
exon
alon
unlik
provid
signific
clinic
benefit
altern
exon
skip
strategi
treatment
consid
dystrophinopathi
patient
mutat
within
exon
duplic
exon
patient
show
normal
develop
grade
slightli
enlarg
calv
also
present
unusu
muscl
atrophi
involv
paraspin
muscl
quadricep
dna
test
reveal
de
novo
infram
delet
dystrophin
exon
muscl
biopsi
perform
tissu
analys
diagnost
laboratori
express
dystrophin
associ
protein
dna
test
reveal
de
novo
infram
delet
dystrophin
exon
deidentifi
patient
normal
human
skin
fibroblast
obtain
inform
consent
univers
western
australia
human
research
ethic
committe
approv
fibroblast
cultur
dmem
life
technolog
melbourn
australia
supplement
foetal
calf
serum
fc
serana
bunburi
australia
gibco
life
technolog
melbourn
australia
uml
penicillin
invitrogen
mgml
streptomycin
life
technolog
ngml
amphotericin
b
sigmaaldrich
sydney
australia
fibroblast
transform
myogen
lineag
transfect
adenovir
construct
express
myod
multipl
infect
nativ
antigen
compani
oxford
uk
cell
differenti
low
serum
media
hsdmem
day
describ
hard
et
al
well
plate
precoat
poli
dlysin
sigma
matrigel
vwr
brisban
australia
hour
respect
patient
normal
fibroblast
seed
x
cellswel
preprepar
well
plate
antisens
oligom
compos
omethyl
modifi
base
phosphorothio
backbon
synthes
expedit
nucleic
acid
synthes
use
reagent
azco
biotech
ca
usa
design
induc
dmd
exon
skip
ao
uac
gag
uug
auu
guc
gga
ccc
anneal
base
exon
shown
induc
specif
exon
skip
panel
splice
switch
ao
develop
excis
mous
dystrophin
exon
target
similar
coordin
use
excis
human
dystrophin
exon
tabl
omethyl
modifi
oligom
uau
gau
uuc
cau
cca
cua
ugu
cag
ugc
uuc
tabl
underlin
anneal
base
mous
dystrophin
exon
identifi
effici
remov
target
exon
vitro
sequenc
synthes
phosphorodiamid
morpholino
oligom
coupl
cell
penetr
peptid
k
ppmo
vivo
experi
myogen
cell
transfect
day
initi
myogen
differenti
ao
complex
lipofectamin
ww
optimem
media
gibco
per
manufactur
instruct
ao
concentr
nm
use
cell
incub
day
rna
extract
total
rna
extract
use
life
technolog
accord
manufactur
instruct
rna
pellet
resuspend
steril
water
baxter
healthcar
australia
approxim
ng
total
rna
use
templat
initi
revers
transcriptas
pcr
reaction
minut
use
iii
onestep
rtpcr
cycl
minut
respect
amplifi
dmd
exon
aliquot
primari
reaction
use
templat
nest
pcr
use
amplitaq
gold
appli
biosystem
melbourn
australia
amplifi
across
dmd
exon
inner
primer
set
cycl
obtain
genework
thebarton
australia
outer
inner
primer
set
span
dmd
exon
describ
robert
et
al
use
amplif
forc
myogen
convers
fibroblast
effici
process
whilst
adequ
rna
studi
degre
myogen
differenti
cultur
make
detail
protein
studi
challeng
normal
patient
fibroblast
propag
trypsinis
genom
dna
harvest
use
pure
genom
dna
kit
life
technolog
pcr
primer
design
gener
amplicon
approxim
across
intron
kb
local
breakpoint
flank
intron
long
rang
pcr
perform
ng
genom
dna
use
takara
la
taq
polymeras
takara
biotechnolog
dalian
co
ltd
japan
la
gc
rich
amplif
buffer
accord
manufactur
instruct
primer
sequenc
shown
tabl
pcr
amplicon
normal
exon
dystrophin
gene
fraction
agaros
gel
imag
captur
fusion
fx
gel
document
system
vilber
lourmat
franc
approxim
locat
breakpoint
intron
identifi
comparison
amplif
product
size
gener
normal
patient
dna
addit
primer
tabl
design
sequenc
intron
junction
use
bigdy
sequenc
chemistri
analysi
australian
genom
research
facil
perth
australia
pcr
product
resolv
agaros
gel
buffer
indic
imag
captur
use
vilber
lourmat
fusion
fx
gel
document
system
experi
perform
anim
approv
univers
western
australia
anim
experiment
committe
approv
number
carri
strict
accord
recommend
nation
health
medic
research
council
australian
code
care
use
anim
scientif
purpos
edit
phosphorodiamid
morpholino
oligom
conjug
cell
penetr
peptid
target
dystrophin
exon
uau
gau
uuc
cau
cca
cua
ugu
cag
ugc
uuc
inject
via
intraperiton
rout
mice
n
induc
dystrophin
isoform
miss
amino
acid
encod
exon
peptid
conjug
suppli
avi
biopharma
inc
bothel
oregon
sarepta
therapeut
resuspend
steril
normal
salin
prewarm
inject
period
begin
day
age
mice
given
twice
weekli
intraperiton
ip
inject
mgkg
mice
assign
control
group
n
mdx
mdx
mice
n
receiv
sham
treatment
contain
equal
volum
normal
salin
mice
anaesthetis
ip
sodium
pentobarbiton
week
complet
treatment
regimen
sampl
physiolog
test
kill
via
cervic
disloc
analysi
diaphragm
muscl
snapfrozen
liquid
nitrogencool
isopentan
store
molecular
histolog
immunofluoresc
studi
end
point
analysi
tissu
sampl
perform
sodium
pentobarbit
anesthesia
effort
made
minim
suffer
approxim
mg
tissu
homogen
mm
trishcl
ph
sd
w
v
glycerol
v
v
mm
phenylmethylsulfonyl
fluorid
proteas
inhibitor
cocktail
sigma
aldrich
sydney
australia
per
tissu
western
blot
carri
essenti
describ
cooper
briefli
dilut
aliquot
protein
extract
total
protein
separ
nupag
bistri
gel
life
technolog
mulgrav
australia
stain
coomassi
blue
destain
acet
acid
gel
densitometri
use
estim
rel
myosin
express
ensur
equal
protein
load
subsequ
gel
western
blot
sampl
contain
total
protein
per
lane
load
onto
gradient
electrophoresi
page
gel
stack
gel
run
mdx
muscl
sampl
use
posit
neg
control
respect
fraction
protein
electroblot
onto
nitrocellulos
membran
amersham
pharmacia
biotech
sydney
australia
overnight
transfer
buffer
mm
trishcl
ph
glycin
methanol
sd
transfer
perform
cool
water
circul
dystrophin
betadystroglycan
detect
probe
membran
monoclon
antidystrophin
novocastra
laboratori
newcastleupontyn
uk
betadystroglycan
primari
monoclon
antibodi
santa
cruz
biotechnolog
respect
signal
develop
use
chemiluminesc
protein
detect
kit
life
technolog
immunodetect
perform
accord
manufactur
protocol
imag
obtain
use
vilber
lourmat
fusion
fx
gel
document
system
band
intens
determin
use
softwar
vilber
lourmat
band
intens
obtain
treatment
group
analys
compar
posit
neg
control
diaphragm
sampl
sham
treat
mdx
control
mice
treat
snap
frozen
liquid
nitrogencool
isopentan
immunochemistri
perform
unfix
serial
cryosect
thick
mice
stain
either
monoclon
polyclon
antibodi
dilut
pbst
contain
normal
goat
serum
collagen
stain
picrosiriu
red
base
method
describ
puchtler
follow
antibodi
use
monoclon
antibodi
novocastra
dystrophin
carboxi
termin
domain
nclmhcd
novocastra
development
myosin
heavi
chain
polyclon
rabbit
antibodi
ab
santa
cruz
antibetadystroglycan
ab
antineuron
nitric
oxid
synthas
nno
millipor
upstat
monoclon
antibodi
detect
perform
use
zenon
alexa
fluor
label
kit
life
technolog
accord
manufactur
recommend
without
fixat
immunofluoresc
stain
complet
nclmhcd
primari
antibodi
use
dilut
molar
ratio
mous
anti
aspergillu
niger
cytochrom
oxidas
dakocytom
code
ab
use
isotyp
neg
control
antibodi
data
shown
goatantirabbit
igg
alexa
fluor
molecular
probe
use
secondari
antibodi
detect
rabbit
polyclon
antibodi
betadystroglycan
neuron
nitric
oxid
synthas
cryosect
incub
room
temperatur
hour
wash
pbst
incub
secondari
antibodi
room
temperatur
hour
wash
pbst
mount
coverslip
antifad
aqueou
mountant
wash
pb
neg
control
prepar
substitut
primari
antiserum
pbst
contain
rabbit
immunoglobulin
fraction
dakocytom
dilut
match
final
immunoglobulin
concentr
duplic
serial
section
olympu
invert
microscop
use
examin
section
imag
captur
olympu
digit
camera
olympu
australia
pti
ltd
sydney
australia
photograph
magnif
set
serial
section
photograph
batch
expos
set
allow
valid
comparison
patient
age
note
around
year
age
enlarg
calv
associ
slow
run
difficulti
climb
stair
use
gower
manoeuvr
rise
floor
around
year
age
concern
regard
inabl
keep
peer
commun
parent
refer
investig
ck
elev
udl
genet
test
show
delet
dmd
exon
diagnos
becker
muscular
dystrophi
age
baselin
cardiac
evalu
normal
echocardiogram
pulmonari
evalu
although
patient
infram
delet
dmd
exon
predict
becker
muscular
dystrophi
diagnosi
sign
symptom
promin
pelvic
girdl
weak
full
time
gower
second
plantigrad
stanc
run
increas
upper
extrem
swing
waddl
unabl
extend
hip
fulli
graviti
tabl
top
manoeuvr
rise
chair
turn
bodi
follow
hand
push
chair
waddl
gait
lordosi
heelto
progress
warrant
investig
diagnost
laboratori
undertook
analysi
limb
girdl
muscular
dystrophi
lgmd
gene
found
sequenc
variant
autosom
recess
lgmd
gene
fkrp
dysf
tcap
ttn
sgca
sgcb
sgce
sgcg
heterozyg
chang
found
exon
undocu
variant
uncertain
clinic
signific
patient
phenotyp
consid
consist
sever
becker
muscular
dystrophi
diagnosi
revis
accordingli
age
nine
half
year
view
find
sever
phenotyp
steroid
therapi
recommend
patient
profil
sinc
diagnosi
dmd
exon
delet
summaris
tabl
muscl
biopsi
patient
analys
indic
dystroph
chang
includ
fibr
size
variat
immunofluoresc
use
ncldi
dystrophin
rod
domain
carboxyterminu
show
reduc
intens
ncldi
aminoterminu
almost
undetect
fig
low
level
dystrophin
detect
western
blot
less
rel
level
normal
healthi
muscl
fig
spectrin
immunostain
sarcolemma
fig
show
muscl
fibr
irregular
size
larg
diamet
fibr
mani
mononuclear
cell
patient
section
normal
muscl
section
show
muscl
fibr
regular
size
shape
typic
healthi
muscl
diagnost
laboratori
report
stain
intens
alphasarcoglycan
merosin
alphadystroglycan
collagen
vi
dysferlin
caveolin
lamin
ac
emerin
appear
normal
data
shown
rtpcr
across
dystrophin
exon
total
rna
extract
patient
myogen
cell
indic
patient
dmd
transcript
miss
exon
sequenc
dystrophin
rtpcr
product
confirm
loss
exon
precis
splice
exon
exon
fig
delet
breakpoint
intron
identifi
gener
kb
amplicon
across
intron
identifi
set
reaction
fail
patient
dna
use
templat
dna
normal
individu
includ
analysi
comparison
amplif
primer
combin
tabl
fail
gener
signal
patient
dna
wherea
normal
dna
gener
product
expect
size
indic
intron
breakpoint
upstream
exon
intron
breakpoint
kb
downstream
exon
subsequ
amplif
patient
dna
revers
primer
target
exon
gener
amplicon
kb
long
rang
pcr
normal
dystrophin
gene
use
primer
gener
product
excess
kb
fig
although
effici
amplif
patientspecif
amplicon
achiev
takara
la
gc
buffer
use
later
buffer
improv
amplif
larger
dystrophin
gene
product
kb
patientderiv
amplicon
use
dna
sequenc
templat
primer
shown
tabl
comparison
refer
sequenc
show
entir
genom
delet
patient
bp
two
common
intron
breakpoint
junction
fig
posit
genom
delet
shown
rel
two
exon
delet
report
lead
dmd
fig
predomin
amplicon
rtpcr
patient
muscl
rna
across
dmd
exon
miss
exon
evid
dmd
transcript
miss
exon
patient
cell
fig
normal
patient
fibroblast
forc
myogen
lineag
transfect
adenoviru
construct
express
myod
transfect
ao
design
excis
dmd
exon
ascertain
recognit
exon
splice
machineri
compromis
patient
delet
shown
fig
effici
exon
skip
transfect
similar
cell
strain
ao
omethyl
modifi
base
phosphorothio
backbon
design
anneal
mous
dystrophin
exon
base
identifi
panel
overlap
oligom
effici
skip
exon
vitro
transfect
primari
mous
myogen
cell
data
shown
sequenc
synthes
pmo
conjug
cell
penetr
peptid
vivo
studi
wild
type
mice
aim
gener
transient
dmd
exon
delet
vivo
model
dystroph
phenotyp
induc
skip
dmd
exon
evid
diaphragm
although
dystroph
patholog
quit
mark
sham
treat
mdx
mice
immunostain
use
antibodi
detect
carboxi
terminu
dystrophin
reflect
patchi
greatli
reduc
stain
diaphragm
treat
mice
compar
sham
treat
control
mice
fig
top
row
western
blot
indic
dystrophin
level
reduc
less
wildtyp
level
data
shown
reduc
dystrophin
stain
associ
reduc
nno
express
diaphragm
treat
mice
fig
left
panel
compar
level
shamtreat
control
mice
fig
central
panel
wherea
express
mdx
mous
diaphragm
low
modest
degre
muscl
regener
diaphragm
treat
mice
indic
presenc
development
myosin
heavi
chain
dmhc
muscl
fibr
fig
neither
muscl
regener
fibrosi
evid
diaphragm
shamtreat
mice
wherea
abund
dmhc
stain
fibrosi
reveal
picrosiriu
red
stain
central
nucleat
appar
treat
sham
treat
mdx
mice
consist
moder
dystroph
muscl
phenotyp
rtpcr
across
dmd
exon
rna
extract
diaphragm
n
sham
treat
mice
sham
treat
mdx
mice
show
effici
skip
exon
vari
total
dmd
transcript
product
determin
densitometri
fig
western
blot
analysi
protein
extract
diaphragm
treat
mice
show
greatli
reduc
dystrophin
express
rel
shamtreat
wild
type
control
fig
percentag
dystrophin
rel
wild
type
control
assess
densitometri
normal
myosin
heavi
chain
express
correl
analysi
dmd
transcript
shown
fig
dystrophin
read
frame
rule
hold
true
dmd
bmd
delet
case
determin
dna
molecular
diagnos
detail
examin
caus
mutat
case
read
frame
except
reveal
sever
mechan
account
discrep
dmd
genotyp
clinic
phenotyp
infram
exon
delet
may
result
sever
phenotyp
delet
involv
exon
result
loss
crucial
function
motif
eg
encod
betadystroglycan
bind
domain
first
exon
protein
truncat
mutat
region
lead
reiniti
translat
exon
synthesi
function
dystrophin
secondari
rna
process
event
appar
analysi
dna
may
influenc
exon
select
process
transcript
nonsens
mutat
infram
exon
encod
dystrophin
rod
domain
manifest
milder
expect
phenotyp
due
natur
skip
mutat
splice
compromis
exon
singl
exon
delet
dmd
ntermin
region
rel
uncommon
entri
leiden
databas
http
wwwdmdnl
describ
delet
exon
although
clinic
detail
patient
minim
three
list
dmd
remain
five
record
intermedi
md
interestingli
seven
entri
duplic
dmd
exon
five
record
report
bmd
phenotyp
one
entri
list
dmd
intermedi
md
detail
dmd
transcript
studi
gualandi
colleagu
report
exon
present
genom
exon
delet
patient
absent
dystrophin
mrna
indic
genom
delet
compromis
exon
recognit
splice
machineri
loss
exon
dmd
transcript
would
disrupt
dystrophin
read
frame
consist
sever
patholog
patient
describ
genom
delet
exon
rna
analysi
indic
exon
miss
dmd
mrna
hypothes
size
andor
locat
particular
frame
delet
compar
kb
delet
identifi
exon
delet
patient
may
contribut
process
dystrophin
exon
splice
gualandi
colleagu
propos
kb
block
sequenc
immedi
upstream
exon
common
dmd
exon
delet
patient
influenc
splice
site
select
novel
fusion
intron
favour
exon
skip
possibl
longer
seem
like
sinc
delet
breakpoint
patient
locat
dmd
exon
delet
patient
report
gualandi
colleagu
possibl
novel
sequenc
kb
delet
breakpoint
may
strengthen
exon
recognit
compar
dmd
exon
delet
clearli
genom
rearrang
subsequ
fusion
normal
noncontigu
sequenc
unexpect
consequ
howev
abl
demonstr
ao
induc
skip
exon
myogen
cell
exon
delet
patient
occur
similar
effici
induc
normal
myogen
cell
suggest
kb
delet
compromis
dystrophin
exon
recognit
process
sinc
delet
exon
disrupt
read
frame
nevertheless
rel
amount
dystrophin
low
assess
western
blot
immunofluoresc
must
assum
qualiti
dystrophin
isoform
lack
amino
acid
encod
exon
compromis
order
explor
function
dystrophin
isoform
miss
domain
encod
exon
use
ao
design
exclud
exon
matur
dmd
transcript
wildtyp
mice
essenti
creat
transient
dystrophinopathi
mous
model
dystrophin
express
localis
muscl
architectur
patient
muscl
reflect
analysi
treat
mous
diaphragm
dystrophin
express
greatli
reduc
betadystroglycan
nno
somewhat
reduc
development
myosin
express
readili
detect
numer
muscl
fibr
muscl
show
increas
collagen
stain
fibr
size
variat
presenc
central
nuclei
indic
activ
muscl
regener
featur
quit
mark
mdx
mous
diaphragm
dystrophin
undetect
apart
occasion
revert
fibr
although
dmd
exon
small
infram
exclus
exon
remov
entir
second
actin
bind
sequenc
appear
sever
compromis
function
dystrophin
isoform
lead
sever
muscl
phenotyp
three
dystrophin
primari
actin
bind
site
ab
specif
amino
acid
encod
dmd
exon
sinc
pathogen
missens
mutat
identifi
region
exon
exon
exon
loss
infram
dystrophin
exon
encod
entir
could
impact
dystrophin
bind
f
actin
issu
complic
frame
delet
dystrophin
isoform
consid
delet
dystrophin
exon
remov
ab
caus
mild
symptom
patient
diagnos
bmd
age
year
although
suggest
need
function
actin
bind
amann
colleagu
report
cluster
basic
repeat
rod
domain
amino
acid
encod
exon
also
bound
factin
secondari
bind
site
contribut
milder
phenotyp
sinc
secondari
bind
domain
would
also
present
dmd
exon
delet
individu
conceiv
spatial
disrupt
remain
ab
compromis
actin
bind
multiexon
frameshift
delet
end
dmd
common
small
infram
delet
like
due
intron
length
also
number
sine
line
alu
repeat
microsatellit
block
howev
report
singl
infram
exon
delet
primari
actinbind
domain
indic
chang
variabl
consequ
two
brother
delet
dmd
exon
show
earli
onset
dystrophi
loss
ambul
stabilis
earli
adulthood
respiratori
cardiac
insuffici
japanes
male
diagnos
autist
age
year
subsequ
found
dmd
delet
exon
report
mild
pseudohypertrophi
modestli
elev
ck
otherwis
normal
muscl
strength
three
affect
brother
found
similar
sever
mental
retard
also
exhibit
muscl
weak
one
specul
autism
relat
dystrophin
isoform
one
famili
dystrophin
isoform
encod
transcript
miss
exon
appear
reduc
function
therefor
clinic
applic
exon
skip
overcom
intraexon
mutat
may
limit
benefit
consequ
simplest
exon
skip
strategi
skip
exon
may
offer
best
outcom
patient
intraexon
mutat
region
gene
delet
dmd
exon
report
associ
mild
bmd
phenotyp
investig
patient
infram
delet
dmd
amino
termin
region
may
help
defin
better
function
dystrophin
isoform
could
induc
ao
mediat
exon
select
